Healthcare Review: Heat Biologics, Sarepta Therapeutics, Auxilium Pharmaceuticals, Galena Biopharma, BioLineRx Print E-mail
By Staff and Wire Reports   
Thursday, 21 August 2014 14:04

U.S. stocks rose Thursday, carrying the S&P 500 index to an intraday record high, after several upbeat economic reports. The S&P 500 added four points, or 0.2%, to 1991 after hitting a record intraday high of 1992.68 earlier in the session. The Dow Jones Industrial Average rose 67 points, or 0.4%, to 17045. The Nasdaq Composite Index slipped two points, or 0.1%, to 4524. Benchmarks climbed higher shortly after Thursday's opening bell and coasted into the early afternoon. Stocks have rallied over the past week, with the S&P 500 on pace for its fourth straight gain.

Shares of thinly-traded nano cap Heat Biologics ($HTBX) jump on a 10x surge in volume (~1.1M) on no news.Shares have languished since last July's IPO at $10. Prices peaked at $15.29 on October 3 and bottomed at $3.60 on August 7.The company's lead product candidate is the cancer immunotherapeutic HS-110 (viagenpumatucel-L) for non-small cell lung cancer.

Sarepta Therapeutics (SRPT) establishes a multi-year multi-product partnership with Colorado-based Flagship Biosciences LLC to develop automated tissue-based quantitative tests related to muscular dystrophy that will support the advancement of Sarepta's product pipeline.

Galena Biopharma ($GALE) appoints Mark W. Schwartz, Ph.D., as President & CEO effective immediately replacing Mark J. Ahn, Ph.D. Previously, Dr. Schwartz was the company's EVP and COO.

Auxilium Pharmaceuticals (NASDAQ:AUXL) announces the results from a Phase 2a clinical trial evaluating the safety and efficacy of injections of collagenase clostridium histolyticum (CCH) for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Three doses (low-0.06mg; mid-0.48mg; high-0.84mg) of CCH showed an improvement in the appearance of cellulite as measured by investigator- and patient-generated scores on the Global Aesthetic Improvement Scale (GAIS).

The USPTO issues a Notice of Allowance to BioLineRx (NASDAQ:BLRX) covering the use of its polymer, BL-7010, for the prevention or decreasing of gluten's deleterious side effects on the gastrointestinal mucosa. The patent, when issued, will be in effect until 2026.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter